[Application of Chimeric Antigen Receptor-Modified NK Cells in Multiple Myeloma]. 2018

Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
Department of Oncology and Hematology, Beijing Huairou Hospital, Beijing 101400, China; Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.

OBJECTIVE To explore the killing effect of CAR (CD138-CD28-CD3ζ)-NK cells on myeloma cells through construction of CAR(CD138-CD28-CD3)-NK cells. METHODS The antiCD138scFv-CD28-CD3 zeta plasmid pcDNA3.1 was constructed, which then together with 3 plasmid lentiviral packaging system were transfected into 293T cells, the virus was collected. Furthermore, in order to get the stably transfected cell line, the NK92MI cell line was infected by the virus, then the positive cells were screened by puromycin. The expression of the CARNK cells were verified by RT-PCR and Western blot. At last the ability of secreting cytokine CD107a was detected by flow cytometry, and the statistical analysis was carried out to verify the anti-myeloma effect of CAR-NK cells. RESULTS Gene fragment of the CAR(antiCD138scFv-CD28-CD3ζ) was constructed successfully by gene engineering technique in vitro, and the gene sequence was verified to be correct by sequencing. By virus packaging technology, the virus expressing the protein of the CAR was obtained. PCR and Western blot verified the expression of CAR fusion protein on the sufurce of NK cells. The cell killing experiment confirmed that the CAR-NK cells possessed the ability to secrete cytokine CD107a superior to control cells and showed the obvious killing effect on multiple myeloma cells. CONCLUSIONS The CAR can be constructed in vitro, and express on NK92 cells. The CAR-NK cells can kill the multiple myeloma cells expressing CD138 antigen, thereby plays an antimyeloma effect.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011946 Receptors, Antigen Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens. Antigen Receptors,Antigen Receptor,Receptor, Antigen
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016086 Lentivirus A genus of the family RETROVIRIDAE consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species. Lentivirinae,Lentiviruses
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
April 2015, Zhongguo shi yan xue ye xue za zhi,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
April 2023, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
December 2023, Hematology/oncology clinics of North America,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
April 2024, Hematology/oncology clinics of North America,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
September 2015, The New England journal of medicine,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
September 2019, International immunopharmacology,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
January 2020, Frontiers in immunology,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
January 2019, Frontiers in immunology,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
January 2016, The New England journal of medicine,
Hua-Ping Wei, and Nan Yang, and Zhen-Yang Gu, and Sha-Sha Zhao, and Fei-Yan Wang, and Lan Luo, and Li-Xun Guan, and Chun-Ji Gao
January 2016, The New England journal of medicine,
Copied contents to your clipboard!